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Eradication	 failure	 of	 H. pylori	 treatments	 for	 children	 increases	
nowadays.	A	goal	of	90%	of	success	must	be	reached	worldwide.	We	
assessed	 the	 effect	 of	 adherence,	 antimicrobial	 susceptibility	 and	
family	awareness	on	treatment	outcome.
Methods:	Open	cross-	sectional	study.	Parents	were	interviewed	to	
evaluate	their	knowledge	about	H. pylori.	A	score	on	15-	point	scale	
was	 construct.	After,	 infected	 children	were	 treated	 either	with	 a	
standard	14-	day	triple	therapy	 (PPI	+	Amoxicillin	+	Metronidazole)	
either	with	PPI	for	3	weeks	before	a	tailored	14-	day	triple	therapy.	
Adherence	 and	 adverse	 events	 were	 assessed	 immediately	 after	
treatment	and	outcome	4	weeks	later	by	stool	antigen	test	(children	
without ulcer) or gastric biopsies (children with ulcers).
Results:	 A	 total	 of	 158	 infected	 children	were	 included	 (75	M/83	
F,	 mean	 age	 7.5	±	2.7,	 range	 3-	14	 year).	 Duodenal	 ulceration	 was	
observed	 in	 12/158	 (7.6%).	 A	 standard	 triple	 therapy	 containing	
metronidazole	was	 prescribed	 in	 110/158	while	 antimicrobial	 sus-
ceptibility was obtained and treatment tailored in the other 48/158 
(triple	therapy	containing	clarithromycin	7/48,	metronidazole	30/48,	
levofloxacin	 6/48	 and	 tetracycline	 5/48).	 Adverse	 events	 occur	 in	
32/158 (20.3%), mainly abdominal pain and diarrhea. Success rate 
was	53/110	 (48.2%)	with	 the	standard	 therapy	and	29/48	 (60.4%)	
with	the	tailored	therapy.	Adherence	of	90%	or	above	was	reached	
by	143/158	and	positively	correlated	with	knowledge	score	(r = 0.17, 
P < 0.05).
Conclusion:	Treatment	strategy	proposed	in	the	ESPGHAN	consen-
sus	 didn’t	 allow	 us	 to	 reach	 the	 90%	 target	 rate	 of	 eradication	 in	
Vietnam.	Increase	the	awareness	on	H. pylori could have a positive 
effect	on	adherence	to	eradication	strategies.
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Background:	Guidelines	recommend	several	antimicrobial	regimens	
for	H. pylori	eradication.	Data	on	the	type	of	regimen	prescribed	in	
clinical practice in Italy are not available yet.
Aim:	To	assess	the	practice	of	gastroenterologists	in	the	treatment	
of	H. pylori	infection	in	Italy.
Methods: The “Italian Registry on H. pylori treatment” is an online 
database prospectively registering adult patients prescribed with 
a	 treatment	 for	 H. pylori	 infection	 by	 gastroenterologists	 in	 Italy.	
Data	were	 collected	 from	 June	2017	 to	May	2108	using	REDCap	
(Research Electronic Data Capture) and an interim analysis was 
performed.
Results:	 A	 total	 of	 485	 patients	 (63.2%	 females,	 mean	 age:	
54.2 years), whose 387 were naive to treatment and 98 had a previ-
ous	treatment	failure,	were	assessed.	At	first-	line	the	most	frequent	
regimen	prescribed	was	 sequential	 therapy	 (169,	 43.7%),	 followed	
by	 the	 new	 formulation	 of	 bismuth	 quadruple	 therapy	 (Pylera®) 
(102,	 26.4%),	 clarithromycin-	containing	 triple	 therapy	 (87,	 22.5%),	
concomitant (27, 7%) and other therapies (2, 0.5%). Most regimens, 
including Clarithromycin- containing triple therapy, were prescribed 
for	10	days.	After	a	previous	treatment	failure,	Pylera®	(59,	60.2%)	
was	the	most	frequent	regimen,	followed	by	levofloxacin-	containing	
triple	 therapy	 (11,	 11.2%),	 rifabutin-	containing	 triple	 therapy	 (9,	
9.2%),	sequential	therapy	(8,	8.2%),	concomitant	(5,	5.1%)	and	other	
therapies	(6,	8.1%).	Probiotics	were	prescribed	in	48.8%	(235/485)	
of	patients.
Conclusions:	Sequential	therapy	and	Pylera® appear to be the most 
frequently	 prescribed	 regimens	 for	 H. pylori eradication in Italy. 
However,	 the	 duration	 of	 clarithromycin-	containing	 triple	 therapy	
was	 shorter	 than	 recommended.	 About	 half	 of	 patients	 received	
probiotics supplementation.
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